The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration

Neuron

Volumn 93, Issue 6, 2017, Pages 1334-1343.e5

  Essuman, Kow ^a   Summers, Daniel W ^a   Sasaki, Yo ^a   Mao, Xianrong ^a   DiAntonio, Aaron ^a   Milbrandt, Jeffrey ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

axonal degeneration; enzyme; innate immunity; NAD+; NADase; SARM1; TIR; Toll interleukin 1 receptor domain

Indexed keywords

GLUTAMIC ACID; GLYCOSIDASE; INTERLEUKIN 1 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; PROTEIN SARM1; UNCLASSIFIED DRUG; ARMADILLO DOMAIN PROTEIN; CYTOSKELETON PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; SARM1 PROTEIN, MOUSE;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MECHANISM; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAMMAL CELL; NERVE DEGENERATION; NERVE FIBER DEGENERATION; OLIGOMERIZATION; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; TRAUMATIC BRAIN INJURY; ANIMAL; AXON; CELL CULTURE; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ARMADILLO DOMAIN PROTEINS; AXONS; CATALYTIC DOMAIN; CELLS, CULTURED; CYTOSKELETAL PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; NAD; NAD+ NUCLEOSIDASE; NERVE DEGENERATION;

EID: 85016048059     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2017.02.022     Document Type: Article

References (44)

1. Araki, T., Sasaki, Y., Milbrandt, J., Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305 (2004), 1010–1013.
2. Armstrong, S.R., Cook, W.J., Short, S.A., Ealick, S.E., Crystal structures of nucleoside 2-deoxyribosyltransferase in native and ligand-bound forms reveal architecture of the active site. Structure 4 (1996), 97–107.
3. Arnold, K., Bordoli, L., Kopp, J., Schwede, T., The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2006), 195–201.
4. Avalos, J.L., Bever, K.M., Wolberger, C., Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17 (2005), 855–868.
5. Berthelier, V., Tixier, J.M., Muller-Steffner, H., Schuber, F., Deterre, P., Human CD38 is an authentic NAD(P)+ glycohydrolase. Biochem. J. 330 (1998), 1383–1390.
6. Burroughs, A.M., Zhang, D., Schäffer, D.E., Iyer, L.M., Aravind, L., Comparative genomic analyses reveal a vast, novel network of nucleotide-centric systems in biological conflicts, immunity and signaling. Nucleic Acids Res. 43 (2015), 10633–10654.
7. Cantó, C., Menzies, K.J., Auwerx, J., NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22 (2015), 31–53.
8. Chen, Z.W., Fuchs, K., Sieghart, W., Townsend, R.R., Evers, A.S., Deep amino acid sequencing of native brain GABAA receptors using high-resolution mass spectrometry. Mol. Cell Proteomics, 11, 2012 M111.011445.
9. Erde, J., Loo, R.R., Loo, J.A., Enhanced FASP (eFASP) to increase proteome coverage and sample recovery for quantitative proteomic experiments. J. Proteome Res. 13 (2014), 1885–1895.
10. Fischer, L.R., Glass, J.D., Axonal degeneration in motor neuron disease. Neurodegener. Dis. 4 (2007), 431–442.
11. Fliegert, R., Gasser, A., Guse, A.H., Regulation of calcium signalling by adenine-based second messengers. Biochem. Soc. Trans. 35 (2007), 109–114.
12. Geisler, S., Doan, R.A., Strickland, A., Huang, X., Milbrandt, J., DiAntonio, A., Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain 139 (2016), 3092–3108.
13. Gerdts, J., Summers, D.W., Sasaki, Y., DiAntonio, A., Milbrandt, J., Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J. Neurosci. 33 (2013), 13569–13580.
14. + destruction. Science 348 (2015), 453–457.
15. Gerdts, J., Summers, D.W., Milbrandt, J., DiAntonio, A., Axon self-destruction: new links among SARM1, MAPKs, and NAD+ metabolism. Neuron 89 (2016), 449–460.
16. Ghosh, J., Anderson, P.J., Chandrasekaran, S., Caparon, M.G., Characterization of Streptococcus pyogenes beta-NAD+ glycohydrolase: re-evaluation of enzymatic properties associated with pathogenesis. J. Biol. Chem. 285 (2010), 5683–5694.
17. Gibson, B.A., Kraus, W.L., New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13 (2012), 411–424.
18. Gilley, J., Coleman, M.P., Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol., 8, 2010, e1000300.
19. Henninger, N., Bouley, J., Sikoglu, E.M., An, J., Moore, C.M., King, J.A., Bowser, R., Freeman, M.R., Brown, R.H. Jr., Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain 139 (2016), 1094–1105.
20. Keller, A., Nesvizhskii, A.I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74 (2002), 5383–5392.
21. Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., Sternberg, M.J., The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10 (2015), 845–858.
22. Kurowska, Z., Kordower, J.H., Stoessl, A.J., Burke, R.E., Brundin, P., Yue, Z., Brady, S.T., Milbrandt, J., Trapp, B.D., Sherer, T.B., Medicetty, S., Is axonal degeneration a key early event in Parkinson's disease?. J. Parkinsons Dis. 6 (2016), 703–707.
23. Liu, Q., Graeff, R., Kriksunov, I.A., Jiang, H., Zhang, B., Oppenheimer, N., Lin, H., Potter, B.V., Lee, H.C., Hao, Q., Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase. J. Biol. Chem. 284 (2009), 27637–27645.
24. Lunn, E.R., Perry, V.H., Brown, M.C., Rosen, H., Gordon, S., Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur. J. Neurosci. 1 (1989), 27–33.
25. Mack, T.G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat. Neurosci. 4 (2001), 1199–1206.
26. Miller, B.R., Press, C., Daniels, R.W., Sasaki, Y., Milbrandt, J., DiAntonio, A., A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Nat. Neurosci. 12 (2009), 387–389.
27. Nesvizhskii, A.I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75 (2003), 4646–4658.
28. O'Neill, L.A., Golenbock, D., Bowie, A.G., The history of Toll-like receptors—redefining innate immunity. Nat. Rev. Immunol. 13 (2013), 453–460.
29. Osterloh, J.M., Yang, J., Rooney, T.M., Fox, A.N., Adalbert, R., Powell, E.H., Sheehan, A.E., Avery, M.A., Hackett, R., Logan, M.A., et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 337 (2012), 481–484.
30. Qiao, F., Bowie, J.U., The many faces of SAM. Sci. STKE, 2005, 2005, re7.
31. Sasaki, Y., Vohra, B.P., Lund, F.E., Milbrandt, J., Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J. Neurosci. 29 (2009), 5525–5535.
32. Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A., Milbrandt, J., NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD(+) depletion. eLife, 5, 2016, e19749.
33. Shimizu, Y., Inoue, A., Tomari, Y., Suzuki, T., Yokogawa, T., Nishikawa, K., Ueda, T., Cell-free translation reconstituted with purified components. Nat. Biotechnol. 19 (2001), 751–755.
34. Sikowitz, M.D., Cooper, L.E., Begley, T.P., Kaminski, P.A., Ealick, S.E., Reversal of the substrate specificity of CMP N-glycosidase to dCMP. Biochemistry 52 (2013), 4037–4047.
35. Söding, J., Biegert, A., Lupas, A.N., The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res., 33, 2005 W244–W228.
36. Summers, D.W., Gibson, D.A., DiAntonio, A., Milbrandt, J., SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation. Proc. Natl. Acad. Sci. USA 113 (2016), E6271–E6280.
37. Tewari, R., Bailes, E., Bunting, K.A., Coates, J.C., Armadillo-repeat protein functions: questions for little creatures. Trends Cell Biol. 20 (2010), 470–481.
38. Villegas, R., Martinez, N.W., Lillo, J., Pihan, P., Hernandez, D., Twiss, J.L., Court, F.A., Calcium release from intra-axonal endoplasmic reticulum leads to axon degeneration through mitochondrial dysfunction. J. Neurosci. 34 (2014), 7179–7189.
39. Walker, L.J., Summers, D.W., Sasaki, Y., Brace, E.J., Milbrandt, J., DiAntonio, A., MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2. eLife, 6, 2017, e22540.
40. Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M.W., He, Z., A local mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol. 170 (2005), 349–355.
41. Wiśniewski, J.R., Zougman, A., Nagaraj, N., Mann, M., Universal sample preparation method for proteome analysis. Nat. Methods 6 (2009), 359–362.
42. Xiong, X., Hao, Y., Sun, K., Li, J., Li, X., Mishra, B., Soppina, P., Wu, C., Hume, R.I., Collins, C.A., The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein. PLoS Biol., 10, 2012, e1001440.
43. Yang, J., Wu, Z., Renier, N., Simon, D.J., Uryu, K., Park, D.S., Greer, P.A., Tournier, C., Davis, R.J., Tessier-Lavigne, M., Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 160 (2015), 161–176.
44. Zhang, Q., Zmasek, C.M., Cai, X., Godzik, A., TIR domain-containing adaptor SARM is a late addition to the ongoing microbe-host dialog. Dev. Comp. Immunol. 35 (2011), 461–468.